Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial

Weekly Q&A – April 27, 2023

Healey Center
Sean M. Healey & AMG Center for ALS at Mass General

Northeast Amyotrophic Lateral Sclerotic Consortium

Harvard Medical School
Massachusetts General Hospital

NEALS
NEUROLOGICAL CLINICAL RESEARCH INSTITUTE
BARROW Neurological Institute

Berry Consultants

seeTHERAPEUTICS
Calico
DENALI THERAPEUTICS

TACKLE ALS
ALS ASSOCIATION
MIDA
Muscular Dystrophy Association

alsFINDINGacure®
I AM ALS

ALS ONE
TAMBOURINE

The Arthur M. Blank Family Foundation

The AMG Foundation
Guest Speaker Judi Carey, RN

Research Access Nurse
Sean M. Healey & AMG Center for ALS
Mass General Hospital
What does a Research Access Nurse do?

- Share Reliable Information
- Advocate for Access
- Provide Hope

Tasks:

- Share specific information about MGH trials
- Provide general research information
- Help to confirm eligibility
- Create recruitment materials
- Connect patients to research centers
- Prescreen patients for trials
Research Access Then & Now & In the Future

- Availability of more research options – PCT, OLE, ATE, EAP
- Incorporation of ZOOM calls
- Increase in access to research locally
- Partnerships with the ALS community
- Formation of the Patient Engagement Team
- Creation of Health Literacy/Definition of DEI
Clinical Trials Enrollment and Coordination

Not sure which trial might be right for you? The Healey Center for ALS offers coordination services to help you understand your options and make the best choice for your individual situation.

Introduction to Clinical Trials

For information or assistance enrolling in clinical trials, please contact:
Judith Carey, RN, ALS Research Access Nurse
Phone: 617-724-8995
Email: mghalsresearch@mgh.harvard.edu

ALS Trials at Mass General

View our currently enrolling ALS research trials at Mass General.

Link to Webpage:
https://bit.ly/3AtEb3u
HEALEY ALS Platform Trial:

- **Regimen A**
- **Regimen B**
- **Regimen C**
- **Regimen D**
- **Regimen E**
- **Regimen F**
- **Regimen G**

Common Protocol and Shared Infrastructure

- Screen for eligibility
- Randomization 3:1
- Placebo
- Active

**Enrollment Complete**

**Enrolling**

**In Start-Up**

- **Screening Period**
- **Randomized Period**
  - 24 weeks
- **Open-Label Extension Period**
  - (Active Treatment Extension)
40 Sites Currently Active for Regimen F

Nova Southeastern University
Essentia Health
Texas Neurology
Mass General Hospital
University of Nebraska
Hospital for Special Care
Henry Ford Hospital
Augusta University
Beth Israel Deaconess
University of Texas HSC
University of Colorado
Loma Linda University
Ohio State University
Cedars Sinai Medical Center
Duke University
Wake Forest University
Saint Alphonsus
UMass Worcester
Lehigh Valley
Thomas Jefferson
University of South Florida
University of Pennsylvania
SUNY Upstate
University of Iowa
California Pacific Med Center
Vanderbilt University
Houston Methodist
University of Minnesota
Washington University
Barrow Neurological Institute
University of Miami
Temple University
University of Virginia
Johns Hopkins University
University of Southern CA
Holy Cross Hospital
University of Washington
University of Utah
Penn State Hershey
University of Michigan

(as of 4/27/23)

Site Map & Contacts:
https://bit.ly/3g2NZr5
Checking Site Status Online

List of Participating Sites

Many sites are expected to start enrolling for Regimen F soon. Sites marked "Recruiting" are currently enrolling participants.

Sites marked "Active, Not recruiting" are active in the Platform Trial (for example, they are following participants in ongoing regimens that have already completed enrollment) but are not enrolling new participants at this time.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Trial Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayo Clinic Florida</td>
<td>FL</td>
<td>Active, Not recruiting</td>
<td>Jany Paulett</td>
</tr>
<tr>
<td>Nova Southeastern University</td>
<td>FL</td>
<td>Recruiting</td>
<td>Donovan Mott</td>
</tr>
</tbody>
</table>

https://bit.ly/3g2NZr5
Regimen F: ABBV-CLS-7262, by Calico and AbbVie - Now Recruiting

ABBV-CLS-7262 is an investigational drug developed by Calico Life Sciences LLC in collaboration with AbbVie Inc. ABBV-CLS-7262 aims to restore function in cells affected by ALS by normalizing protein synthesis and preventing further sequestration and aggregation of TDP-43, thereby protecting neurons, and possibly slowing ALS progression.

The integrated stress response (ISR) is a fundamental transient process that regulates cell function during various stressful conditions. Tissue studies suggest that the ISR is chronically induced in people with ALS. It is proposed that TDP-43 aggregates, a hallmark feature in the motor neurons of people with ALS, could be formed by a chronically induced ISR. ABBV-CLS-7262 activates the protein complex eIF2B, which is a key regulator of the ISR. Binding of ABBV-CLS-7262 desensitizes eIF2B to stress and decreases the ISR. Reduction of the ISR restores normal protein synthesis, reduces TDP-43 sequestration in stress granules, and may decrease TDP-43 aggregation.

A prior first-in-human study of ABBV-CLS-7262 showed that this drug was well-tolerated by participants, demonstrated target engagement by increasing eIF2B enzymatic activity, and suppressed the ISR in blood cells. ABBV-CLS-7262 crossed the blood brain barrier at concentrations predicted to be efficacious in ALS. ABBV-CLS-7262 is currently being investigated in a Phase 1b study in people with ALS (NCT04948645), and will be studied further as part of the HEALEY ALS Platform Trial.

Watch this video for more information on the mechanism of action behind ABBV-CLS-7262.

Download brochure

Topic: Regimen F Drug Science and Mechanism of Action

Recording Available: [https://bit.ly/3mQy5qQ](https://bit.ly/3mQy5qQ)
The ALS Association/Northeast ALS Consortium Educational Webinar

Why lumbar puncture and CSF biomarkers are important to ALS therapeutic development

Presenter: Nicholas J. Maragakis, M.D., Johns Hopkins University

Monday, May 8th
1:00 – 2:00pm Eastern

Register Here:
https://bit.ly/3JTZqzN

Recording will later be available under “educational webinars” on neals.org
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:
https://bit.ly/3r6Nd2L

ALS Link sign-up:
https://bit.ly/3o2Ds3m

Upcoming Webinars:
May 4th- Weekly Q&A
May 11th- Weekly Q&A